Silvia Fonquerna Pou

USPTO Granted Patents = 11 (Patent Applications = 1)

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 9)

Average Co-Inventor Count = 4.2

ph-index = 3

Forward Citations = 46(Granted Patents)

Company Filing History:

Laboratorios Almirall, S.a.

patents

2 out of 10

Almirall Prodesfarma S.a.

patents

Years Active: 2004-2019

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10214509 - Amino-substituted heterocyclic derivatives as sodium channel inhibitors (2019-02-26),

2. 10173985 - Aminoindazole derivatives as sodium channel inhibitors (2019-01-08),

3. 9643961 - Cyclohexylamine derivatives having β2 adrenergic antagonist and M3 muscarinic antagonist activities (2017-05-09),

4. 9518050 - Cyclohexyl and quinuclidinyl carbamate derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activity (2016-12-13),

5. 9315463 - Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities (2016-04-19),

6. 8536165 - Azabiphenylaminobenzoic acid derivatives as DHODH inhibitors (2013-09-17),

7. 7855202 - [object Object] (2010-12-21),

8. 7622480 - Azaindolylpiperidine derivatives as antihistaminic and antiallergic agents (2009-11-24),

9. 7560471 - Indolylpiperidine derivatives as potent antihistaminic and antiallergic agents (2009-07-14),

10. 7189741 - Indolylpiperidine derivatives as antihistaminic and antiallergic agents (2007-03-13),

11. 6683096 - Indolylpiperidine derivatives as antihistaminic and antiallergic agents (2004-01-27),

Title: The Innovative Work of Barcelona-Based Inventor Silvia Fonquerna Pou

Introduction: Silvia Fonquerna Pou is a prolific inventor based in Barcelona, Spain, with an impressive portfolio of 11 patents to his name. His groundbreaking inventions in the field of pharmaceuticals and health care have made significant contributions to the medical industry.

Latest Patents: Among his latest patents is the development of amino-substituted heterocyclic derivatives as sodium channel inhibitors. These compounds have shown promise in treating diseases mediated by modulation of voltage-gated sodium channels, specifically Nav1.7. Additionally, Silvia Fonquerna Pou has successfully patented aminoindazole derivatives as sodium channel inhibitors, showcasing his innovation in pharmaceutical research.

Career Highlights: Silvia Fonquerna Pou has held key roles at renowned companies such as Almirall, S.A. and Laboratorios Almirall, S.A. His expertise and dedication to research and development have helped these companies push the boundaries of medical innovation and improve patient care worldwide.

Collaborations: Throughout his career, Silvia Fonquerna Pou has collaborated with esteemed professionals in the industry, including Carlos Puig Duran and Jose Aiguade Bosch. These collaborations have fostered creativity, knowledge sharing, and innovation in the pharmaceutical field.

Conclusion: In conclusion, Silvia Fonquerna Pou's inventive spirit and dedication to advancing medical research have solidified his position as a respected inventor in the industry. His patents and collaborations stand as a testament to his ongoing commitment to driving innovation and making a positive impact on global healthcare.

This text is generated by artificial intelligence and may not be accurate.